About our parent company
MKT Pharma — credentials
Vinapharma is the international partnership division of MKT Pharma, established in January 2019 and among Vietnam’s largest pharmaceutical distributors. Our scale, regulatory expertise, and hospital relationships are what international partners hire us for.
MKT Pharma at a glance
Hospital footprint
Selected key accounts. Our reps work across these institutions daily; tender wins translate directly into shelf placement.
Ha Noi & North
- K Hospital
- Bach Mai Hospital
- Hanoi Oncology Hospital
- Hanoi Medical University Hospital
- National Institute of Hemato and Blood Transfusion
- Viet Tiep Hai Phong
- Nghe An Oncology Hospital
- Thanh Hoa Oncology
Center & Highland
- Hue Central Hospital
- Hue University Hospital of Medicine & Pharmacy
- Da Nang Oncology Hospital
- Khanh Hoa Oncology
- Tay Nguyen General Hospital
HCMC & South
- Cho Ray Hospital
- HCMC Oncology Hospital
- HCMC Medical University Hospital
- Military Hospital 175
- Blood Transfusion Haematology (BTH) Hospital
- Can Tho Oncology Hospital
- Kien Giang Oncology Hospital
- Bac Lieu General Hospital
Top private hospitals targeted for innovative launches: FV Hospital · Vinmec · Tam Anh.
Existing partners
Selected; full roster shared on request.
Oncology portfolio
A representative slice of our current oncology line. Top-13 sellers in 2025 include Biratiga 500 (Bicalutamide), Glidvak 400mg (Imatinib), Geastine 250 (Afatinib), and Erlovtar 150 (Erlotinib).
| Product | Molecule | Indication |
|---|---|---|
| Palciclib 75 / 100 / 125 | Palbociclib | Breast cancer (CDK4/6 inhibitor) |
| Fulvestrant Ever Pharma 250mg | Fulvestrant | HR+ breast cancer |
| Capbize 500mg | Capecitabine | Multiple oncology |
| Osimertinib 80mg | Osimertinib | EGFR+ NSCLC (3rd-gen TKI) |
| Fasetin | Palonosetron 500mcg | CINV antiemetic |
| Clexza | Venetoclax 100mg | CLL, AML |
| Zolodal Tab 100 | Temozolomide | Glioblastoma |
| Lenazol | Letrozole 2.5mg | Breast cancer (aromatase inhibitor) |
Case studies
Originator oncology partnership
Distribution and tender wins for a European originator across Vietnam's oncology centers; expanded from 3 to 14 hospital placements within 18 months of launch.
EU-GMP generic launch in cardiovascular-metabolic
DAV registration → tender Group 2 placement → 4,000+ pharmacy distribution in 14 months for a Polish EU-GMP generic.
Ready to see specifics for your molecule?
We share a 2-page Vietnam Market Entry Brief with tender volumes, current originator, regulatory pathway, and our hospital reach for your therapeutic area.
Request a brief